Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Sep. 30, 2026

Schedule of information by level for financial assets and liabilities that are measured at fair value on a recurring basis

The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):


		* *	Total
			carrying
			value as of			Fair Value Measurements Using
	Balance Sheet Location		September 30,			Inputs Considered as
			2026			Level 1		Level 2		Level 3
Assets
Exchange traded securities⁽¹⁾	Other current assets		$	1,092		$	1,092	$	—	$	—
Notes receivable⁽²⁾	Other current assets			6,741			—		—		6,741
Notes receivable⁽²⁾	Other assets			3,601			—		—		3,601
Total assets			$	11,434		$	1,092	$	—	$	10,342

Liabilities
Derivatives designated as hedging instruments - net investment hedge	Other long-term liabilities		$	9,853		$	—	$	9,853	$	—
Total liabilities			$	9,853		$	—	$	9,853	$	—

(1)Exchange traded securities received from the buyer in the sale of Exosome Diagnostics.

(2)Notes receivable relate to the divestiture of our businesses held-for-sale.


		* *	Total
			carrying
			value as of			Fair Value Measurements Using
	Balance Sheet Location		June 30,			Inputs Considered as
		* *	2026			Level 1		* *	Level 2		* *	Level 3
Assets
Exchange traded securities⁽¹⁾	Other current assets		$	767		$	767		$	—		$	—
Note receivable⁽²⁾	Other current assets			3,913			—			—			3,913
Note receivable⁽²⁾	Other assets			7,560			—			—			7,560
Total assets			$	12,240		$	767		$	—		$	11,473

Liabilities
Derivatives designated as hedging instruments - net investment hedge	Other long-term liabilities		$	14,712		$	—		$	14,712		$	—
Total liabilities			$	14,712		$	—		$	14,712		$	—

(1)	Exchange traded securities received from the buyer in the sale of Exosome Diagnostics.

(2)Notes receivable relate to the divestiture of our businesses held-for-sale.

Schedule of reconciliation of the notes receivable measured on a recurring basis using significant unobservable inputs (Level 3)

The following table presents a reconciliation of the notes receivable measured on a recurring basis using significant unobservable inputs (Level 3) (in thousands):


	September 30,		June 30,
	2026		2026
Beginning balance	$	11,473	$	5,262
Additions		—		9,000
Payments received		(131)		(1,973)
Changes in fair value included in earnings		(1,000)		(816)
Ending balance	$	10,342	$	11,473

Schedule of contractual amounts of the outstanding instruments

The following table presents the contractual amounts of the Company's outstanding instruments (in millions):


		* *	September 30,		June 30,
Instruments	Designation	* *	2026		2026
Cross-currency swap⁽¹⁾	Net investment hedge			120		130

⁽¹⁾

In July 2023, the Company entered into a pay-fixed rate, receive-fixed rate cross-currency swap contract with a total notional amount of $150 million that was designated as a hedge to lock in the Swiss franc (CHF) rate for a portion of the Company's CHF net investment in its Lunaphore subsidiary in Switzerland. The objective of the hedge is to protect the net investment in the Company's CHF-denominated operations against changes in the spot exchange rates, on a pre-tax basis. The hedging instrument has three remaining interim settlement dates, which will reduce the notional on the hedging instrument by $10 million at each interim date, and will reduce the notional to $110 million at maturity.

Schedule of pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses

The pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses within our Condensed Consolidated Financial Statements for the quarters ended September 30, 2026 and 2025 were as follows (in thousands):


		(Gain) Loss Recognized in Accumulated Other Comprehensive Loss
	* *	Quarter Ended
		September 30,
	* *	2026		2025
Cash flow hedges
Forward starting swaps		$	—	$	3,009
Net investment hedges
Cross-currency swap			(3,154)		(717)
Total		$	(3,154)	$	2,292


		Gain Reclassified into Income
	* *	Quarter Ended
		September 30,				Income Statement
	* *	2026		2025		Classification
Cash flow hedges
Forward starting swaps		$	—	$	(1,921)	Interest expense
Net investment hedges
Cross-currency swap			(726)		(613)	Interest expense
Total		$	(726)	$	(2,534)

- Definition

Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.

+ References + Details